Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:EMC NYSEAMERICAN:PFNX TSE:RVX NASDAQ:TLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEMCEMC$29.00-0.8%$0.00$22.99▼$29.13N/AN/A13.90 million shs1,207 shsPFNXPfenex$12.75$12.75$5.26▼$14.00$437.29MN/A503,865 shsN/ARVXResverlogixC$0.06+22.2%C$0.04C$0.04▼C$0.10C$10.89M0.7168,866 shs100,166 shsTLXTelix Pharmaceuticals$15.57-2.5%$16.68$13.61▼$30.36$5.27BN/A29,204 shs36,541 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEMCEMC0.00%-0.94%+1.22%+15.69%+3.19%PFNXPfenex0.00%0.00%0.00%0.00%0.00%RVXResverlogix0.00%-10.00%+28.57%+12.50%-10.00%TLXTelix Pharmaceuticals0.00%-0.96%-0.75%-5.17%+1,596,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEMCEMCN/AN/AN/AN/AN/AN/AN/AN/APFNXPfenexN/AN/AN/AN/AN/AN/AN/AN/ARVXResverlogixN/AN/AN/AN/AN/AN/AN/AN/ATLXTelix PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEMCEMC 0.00N/AN/AN/APFNXPfenex 0.00N/AN/AN/ARVXResverlogix 0.00N/AN/AN/ATLXTelix Pharmaceuticals 3.00Buy$22.3343.44% UpsideCurrent Analyst Ratings BreakdownLatest PFNX, EMC, TLX, and RVX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/9/2025TLXTelix PharmaceuticalsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform7/3/2025TLXTelix PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$23.006/12/2025TLXTelix PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$22.006/5/2025TLXTelix PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$22.00(Data available from 7/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEMCEMCN/AN/AN/AN/AN/AN/APFNXPfenexN/AN/AN/AN/AN/AN/ARVXResverlogixN/AN/AC$0.00 per share132.50C($0.23) per shareN/ATLXTelix Pharmaceuticals$783.21M6.73$0.11 per share139.85$1.12 per share13.90Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEMCEMCN/A$2.0514.15∞N/AN/AN/AN/AN/APFNXPfenexN/AN/A0.00∞N/AN/AN/AN/AN/ARVXResverlogix-C$2.81M-C$0.02N/A∞N/AN/A6.06%-34.90%N/ATLXTelix Pharmaceuticals$32.93MN/A0.0032.44N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEMCEMC$0.461.59%N/A22.44%N/APFNXPfenexN/AN/AN/AN/AN/ARVXResverlogixN/A7.02%N/AN/AN/ATLXTelix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEMCEMCN/AN/AN/APFNXPfenexN/AN/AN/ARVXResverlogix-10.950.130.04TLXTelix Pharmaceuticals0.992.782.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEMCEMC79.86%PFNXPfenexN/ARVXResverlogixN/ATLXTelix PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipEMCEMC0.40%PFNXPfenexN/ARVXResverlogix42.66%TLXTelix PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEMCEMCN/AN/AN/ANot OptionablePFNXPfenex7134.30 millionN/ANot OptionableRVXResverlogix19197.94 millionN/ANot OptionableTLXTelix PharmaceuticalsN/A338.38 millionN/AN/APFNX, EMC, TLX, and RVX HeadlinesRecent News About These CompaniesWilliam Blair Reiterates Outperform Rating for Telix Pharmaceuticals (NASDAQ:TLX)July 12 at 2:23 AM | americanbankingnews.comTelix Pharmaceuticals (TLX) Announces That Gozellix® is Commercially ...July 11 at 11:53 PM | insidermonkey.comTelix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - Should You Sell?July 10, 2025 | marketbeat.comGozellix Receives Permanent HCPCS CodeJuly 9, 2025 | globenewswire.comTelix Pharmaceuticals (NASDAQ:TLX) Shares Gap Up - What's Next?July 9, 2025 | marketbeat.comTelix Pharmaceuticals (NASDAQ:TLX) Receives "Outperform" Rating from William BlairJuly 9, 2025 | marketbeat.comTelix shares jump 7% on big US newsJuly 8, 2025 | msn.comHC Wainwright Begins Coverage on Telix Pharmaceuticals (NASDAQ:TLX)July 5, 2025 | americanbankingnews.comTelix Pharmaceuticals Stock Short Interest Report | NASDAQ:TLX - BenzingaJuly 3, 2025 | benzinga.comHC Wainwright & Co. Initiates Coverage of Telix Pharmaceuticals Limited - Depositary Receipt () (TLX) with Buy RecommendationJuly 3, 2025 | msn.comTelix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - Here's What HappenedJuly 3, 2025 | marketbeat.comTelix Pharmaceuticals (NASDAQ:TLX) Coverage Initiated at HC WainwrightJuly 3, 2025 | marketbeat.comUp 36% in a year, why this $8 billion ASX 200 stock has still a 'strong growth forecast'June 30, 2025 | msn.comTelix Pharmaceuticals (NASDAQ:TLX) Sees Unusually-High Trading Volume - Here's What HappenedJune 27, 2025 | marketbeat.comTelix Pharmaceuticals Limited: Telix Manufacturing Solutions Belgium Delivers First GMP-Grade Commercial DosesJune 25, 2025 | finanznachrichten.deTelix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - What's Next?June 23, 2025 | marketbeat.comIlluccix Approved in U.S. for Patient Selection for Pre-Taxane RLTJune 23, 2025 | globenewswire.comTelix Pharmaceuticals (NASDAQ:TLX) Sees Large Volume Increase - Time to Buy?June 20, 2025 | marketbeat.comTelix Precision Medicine Announces AlFluor Radiochemistry PlatformJune 20, 2025 | globenewswire.comTelix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025June 19, 2025 | globenewswire.comWedbush Initiates Coverage of Telix Pharmaceuticals Limited - Depositary Receipt () (TLX) with Outperform RecommendationJune 5, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePFNX, EMC, TLX, and RVX Company DescriptionsEMC NYSE:EMCEMC Corporation (EMC) develops, delivers and supports the information technology (IT) industry's range of information infrastructure and virtual infrastructure technologies, solutions and services. EMC manages the Company as part of a federation of businesses: EMC Information Infrastructure, VMware Virtual Infrastructure, Pivotal and Virtustream. EMC's Information Infrastructure business provides a foundation for organizations to store, manage, protect, analyze and secure information. EMC's VMware Virtual Infrastructure business is engaged in virtualization and cloud infrastructure solutions that enable businesses to help transform the way they build, deliver and consume IT resources in a manner that is based on their specific needs. EMC's Pivotal business unites strategic technology, people and programs from EMC and VMware and has a platform that consists of data, agile development practices and a cloud independent platform-as-a-service.Pfenex NYSEAMERICAN:PFNX$12.75 0.00 (0.00%) As of 10/1/2020Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.Resverlogix TSE:RVXC$0.06 +0.01 (+22.22%) As of 12:32 PM EasternResverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.Telix Pharmaceuticals NASDAQ:TLX$15.57 -0.40 (-2.50%) Closing price 04:00 PM EasternExtended Trading$16.06 +0.49 (+3.15%) As of 04:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUranium CarUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Insider Selling Hits Market Leaders—Should You Be Worried? MP Materials Stock Booms on New Government Positioning MarketBeat Week in Review – 07/07 - 07/11 How Texas Roadhouse Is Winning in a Changing Consumer Market Power Solutions International Poised for 75% Upside The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? 3 Catalysts Converge on Intel Ahead of a Critical Earnings Report Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
